Abstract: An organic metal complex is provided. The organic metal complex has formula (I): wherein R1 includes hydrogen, C1˜C9 alkyl, C5˜C8 cycloalkyl, or substituted or non-substituted aromatic groups, R2 and R3 comprise hydrogen, fluorine, trifluoromethyl, C1˜C9 alkyl, C5˜C8 cycloalkyl, or substituted or non-substituted aromatic groups, Y comprises C—R or carbonyl, wherein R comprises hydrogen, C1˜C9 alkyl, C5˜C8 cycloalkyl, or substituted or non-substituted aromatic groups, L is a ligand, M comprises iridium, platinum, ruthenium, gold, or palladium, m is 1˜3, and n is 0˜2, wherein m+n is equal to the valence of M.
Type:
Grant
Filed:
July 13, 2007
Date of Patent:
September 21, 2010
Assignee:
Industrial Technology Research Institute
Inventors:
Chih-Lung Chin, Wan Chi Chen, Kung-Lung Cheng
Abstract: A process for preparing perylene-3,4-dicarboximides which bear a sterically demanding substituent on the imide nitrogen atom by reacting a perylene-3,4:9,10-tetracarboxylic dianhydride with a sterically hindered primary amine in a substantially anhydrous reaction medium, which comprises undertaking the reaction in the presence of a tertiary amine, of a solvent based on a cyclic imine or amide and of a Lewis acid as a catalyst.
Type:
Grant
Filed:
November 4, 2005
Date of Patent:
September 21, 2010
Assignee:
BASF Aktiengesellschaft
Inventors:
Martin Koenemann, Peter Blaschka, Helmut Reichelt
Abstract: This invention is directed to spiroheterocyclic compounds of formula (I) wherein k, j, p, Q, R1, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.
Type:
Grant
Filed:
April 11, 2006
Date of Patent:
September 21, 2010
Assignee:
Xenon Pharmaceuticals Inc.
Inventors:
Mikhail Chafeev, Sultan Chowdhury, Robert Fraser, Jianmin Fu, Rajender Kamboj, Shifeng Liu, Mehran Seid Bagherzadeh, Jianyu Sun, Serguei Sviridov
Abstract: A charge-neutral organometallic dendrimer is described, said dendrimer having the formula (I): CORE-[DENDRITE(-Q)a]n??(I) in which CORE represents a group of formula MXxYz, in which M represents a metal cation, x represents an integer of 1 or more, each X which may be the same or different represents a mono-, bi- or tri-dentate coordinating group, z represents 0 or an integer of 1 or more, and each Y which may be the same or different represents a coordinating group, the total of (b.x)+(c.
Type:
Grant
Filed:
August 28, 2003
Date of Patent:
September 21, 2010
Assignees:
Isis Innovation Limted, The University Court of the University of St. Andrews
Inventors:
Ifor David William Samuel, Paul Leslie Burn, Shih-Chun Lo
Abstract: A method for preparing a perylene pigment or perinone pigment involves a condensation reaction between perylene tetracarboxylic acid or naphthalene tetracarboxylic acid, or anhydrides or imides thereof, and amines in the presence of certain metal catalysts, such as ammonium molybdate, molybdenum oxide, and metal carbonyls, such as hexacarbonylmolybdenum, titanium carbonyl, iron carbonyls, and the like. The use of these catalysts provides various advantages, including the reduction of the amount of the catalyst, while achieves high yields, the lowering of reaction temperatures, and the reduction of insoluble sludge in the reaction mixture, thereby making the reaction operation easier and reducing the amounts of hazardous wastes containing heavy metals.
Abstract: Compounds of Formulas I-II are described, along with methods of using such compounds for the treatment of cancer and pharmaceutical formulations thereof.
Type:
Grant
Filed:
January 16, 2009
Date of Patent:
September 14, 2010
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
Kuo-Hsiung Lee, Xihong Wang, Kenneth F. Bastow, Tian-Shung Wu
Abstract: The optically active compound (R)-2-amino-1,4-dihydro-6-methyl-4-(3 -nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl) ester 5 -isopropyl ester or a pharmacologically acceptable salt thereof, and a method using the compound or its salt to treat circulatory diseases.
Abstract: Alkaloid reaction products obtainable in a process wherein alkaloids are reacted with an alkylating agent, preferably thiotepa, whereafter unreacted alkylating agent and other water-soluble compounds are removed from the reaction mixture by washing with water or a suitable aqueous solvent, whereafter the reaction mixture is subjected to a treatment with strong acid, preferably hydrogen chloride (HCl), to precipitate a water soluble salt of the reaction products. The precipitated reaction products comprise at least one quaternary alkaloid derivative and are suitable as drugs for prophylactic or therapeutic application, particularly in the treatment of immunological or metabolic dysfunctions, and cancer.
Abstract: Disclosed herein are a di-(4-vinylpyridine) metal phthalocyanine compound in which 4-vinylpyridines as ligands are included in a phthalocyanine having a metal, a composition comprising the same and a preparation method thereof. The di-(4-vinylpyridine) metal phthalocyanine compound has an excellent UV blocking effect together with low surface resistance and is prepared but by charging a powder phase with nitrogen, not by dissolving raw materials in an organic solvent as in the prior art.
Type:
Grant
Filed:
December 24, 2008
Date of Patent:
September 7, 2010
Assignee:
Hoseo University Academic Cooperation Foundation
Inventors:
Young Goo Kang, Dae Woo Ihm, Shi Surk Kim
Abstract: A dye for a dye sensitized photovoltaic cell is disclosed. A dye sensitized photovoltaic cell including the dye is also disclosed. The dye includes a metal composite treated with a cation selected from imidazolium cations, pyridinium cations, pyrrolidinium cations, and quinolidinium cations.
Abstract: Lipophilic anticancer drug compounds, compositions that include the compounds, and methods for treating a cell proliferative disease using the compounds.
Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.
Type:
Grant
Filed:
July 21, 2009
Date of Patent:
August 31, 2010
Assignee:
Pfizer Inc.
Inventors:
Hengmiao (Henry) Cheng, Rajesh Devraj, Gary A Decresenzo, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
Abstract: A carboxylic acid derivative of formula (I): wherein R1 is —COOH, —COOR6, etc.; A is a single bond, alkylene, etc.; R2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE2 receptor, especially subtypes EP3 and/or EP4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.
Abstract: Lipophilic di(anticancer drug) compounds, compositions that include the compounds, and methods for treating a cell proliferative disease using the compounds.
Abstract: A novel compound of the formula (I): wherein R1 is alkoxycarbonyl or the like, R2 is alkyl or the like; R3 is hydrogen or the like; R4 is alkylene or the like; R5 is optionally substituted heterocyclic group; R6, R7, and R8 are independently hydrogen; alkyl, alkoxy, or the like; R10 is optionally substituted aromatic ring, or the like; or a pharmaceutically acceptable salt thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP).
Abstract: Substituted indenoisoquinolinium compounds, and pharmaceutical formulations of substituted indenoisoquinolinium compounds are described. Also described are processes for preparing substituted indenoisoquinolinium compounds. Also described are methods for treating cancer in mammals using the described substituted indenoisoquinolinium compounds or pharmaceutical formulations thereof.
Type:
Grant
Filed:
March 15, 2005
Date of Patent:
August 24, 2010
Assignees:
Purdue Research Foundation, The United States of America as represented by the Department of Health and Human Services
Inventors:
Mark S. Cushman, Alexandra S. Ioanoviciu, Yves G. Pommier
Abstract: Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein An, En, Mn, Un, Gn, Jn, Kn, R9, R10, R11, R32, R33, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
Type:
Grant
Filed:
March 29, 2006
Date of Patent:
August 17, 2010
Assignee:
Schering Corporation
Inventors:
Samuel Chackalamannil, Mariappan V. Chelliah, Yan Xia
Abstract: There are provided compounds of the formula and pharmaceutically acceptable salts and esters and enantiomers thereof wherein W, X, X?, Y, V, V?, A, B and R are as described herein. The compounds have utility as antiproliferative agents, especially, as anticancer agents.
Type:
Grant
Filed:
November 18, 2008
Date of Patent:
August 17, 2010
Assignee:
Hoffman-La Roche Inc.
Inventors:
Li Chen, Xingchun Han, Yun He, Song Yang, Zhuming Zhang